Income before deduction of interest, taxes and amortization: Adlai Nortye Ltd. (ANL)
The growth of Adlai Nortye Ltd. (ANL) is based on the results of global oncology drug trials and their commercialization. The volume of EBITDA on this GURU.Markets service chart confirms this trend, where 0.00 captures the magnitude of this parameter. Stability is ensured by the company's status as a reliable partner in tumor therapy and management's ability to adapt programs to global regulatory standards.
Summary analytical data breakdowns for Adlai Nortye Limited (ANL)
- market price and analyst price targets:
- company stock exchange capitalization indicators:
- book capitalization information:
- business debt structure and liquidity details:
Debt to Equity Ratio Adlai Nortye Ltd.|ANL - Long-Term Debt to Equity|Short-Term Debt to Equity Adlai Nortye Limited|ANL - Company Aggregate Debts|Debts to Book Capitalization Adlai Nortye Ltd.|ANL - Company Long-Term Debts|Short-Term Debt Volume Adlai Nortye|Intermediate Coverage Ratio adlainortye.com
- earnings and market multiples details:
ANL - Company Net Income|Net Profit Forecast Adlai Nortye Ltd.|ANL - Price to Earnings Ratio|Projected Price to Earnings Ratio Adlai Nortye Ltd.|ANL - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Adlai Nortye Limited|ANL - Operating profit before deduction of amortization|Earnings per share for the last four quarters Adlai Nortye|ANL - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months adlainortye.com|ANL - Earnings growth in current year|Expected net earnings per share growth next year Adlai Nortye Ltd.
- sales revenue and business income indicators:
Summary company analytics:ANL (adlainortye.com)
To assess the financial stability of Adlai Nortye Ltd. (ANL), it is critical to track the business's actual ability to generate cash flow from core operations. This metric measures operating profit before depreciation and amortization, and this EBITDA chart allows for a comparison of the actual monetization of oncology developments against clinical trial successes, determining the company's potential for commercial scaling in the US and Chinese markets.
Who Adlai Nortye Ltd. competes with
Operating profit EBITDA beigene.com ONC|HALO: Operating profit before deduction of amortization|RVMD - Operating profit EBITDA|Ascentage (AAPG) - Profit before payment of interest, taxes and amortization|CG Oncology Corp - Income before deduction of interest, taxes and amortization|URGN (UroGen Pharma Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization Bicara Therapeutics Inc. BCAX|Profit before payment of interest, taxes and amortization Personalis, Inc. (PSNL)|ERAS - Profit before interest, taxes and amortization|Operating profit EBITDA DCTH (delcath.com)|Operating profit before depreciation charges Y-mAbs Corp|AURA - Profit before payment of interest, taxes and amortization|CADL (candeltx.com) - Operating profit before amortization|ARAY (accuray.com) - Operating profit before deduction of amortization|SELLAS Life Sciences Group Inc. (SLS) - Operating profit EBITDA|ACTU (Actuate Therapeutics Inc.) - Operating profit EBITDA|Operating profit EBITDA Citius Oncology Inc|Operating profit EBITDA HURA|TARA (Protara Therapeutics) - Income before deduction of interest, taxes and amortization|Operating profit EBITDA FATE (Fate Therapeutics)|Operating income before deduction of amortization Aadi Bioscience Inc (WHWK)|TScan Therapeutics, Inc. - Operating profit EBITDA|CSBR (Champions Oncology, Inc.) - Operating profit before amortization|XBIT (XBiotech USA) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization CEL-SCI Corp (CVM)|OSTX (OS Therapies Inc.) - Operating profit EBITDA|Operating profit before deduction of amortization Radiopharm Theranostics (RADX)|Operating profit before deduction of amortization ARTV (Artiva Biotherapeutics, Inc.)|VERU - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Tempest Therapeutics TPST|xiliotx.com (XLO) - Profit before interest, taxes and amortization|RENB: Operating profit before deduction of amortization|Operating profit before depreciation charges Mural Oncology PLC (MURA)|KAPA (Kairos Pharma Inc) - Operating profit before deduction of amortization|Profit before interest, taxes and amortization OnKure Therapeutics Inc (OKUR)|GDTC (CytoMed Therapeutics Ltd) - Operating profit EBITDA|Operating profit before deduction of amortization Curis, Inc. (CRIS)|Operating profit EBITDA APLM|Company profit before taxes, interest and amortization THAR|Operating profit EBITDA ADVB (advanbiomed.com)|GNPX - Operating profit before deduction of amortization|CLDI: Operating profit before deduction of amortization|SBFM - Operating profit EBITDA|Xenetic Biosciences (XBIO) - Profit before payment of interest, taxes and amortization|SLRX: Company profit before taxes, interest and amortization|PPBT (Purple Biotech Ltd) - Operating profit EBITDA|Profit before interest, taxes and amortization American Oncology Network, Inc. AONC|Operating profit EBITDA BGNE|Operating income before deduction of amortization Checkpoint Therapeutics|Elevation Oncology, Inc. - Operating profit before deduction of amortization|Operating profit EBITDA iCAD, Inc. ICAD|Ikena Oncology, Inc. - Operating profit EBITDA|NTBL - Operating profit EBITDA|VIRX (Viracta Therapeutics) - Operating profit before deduction of amortization|MorphoSys AG - Income before deduction of interest, taxes and amortization|NAYA (NAYA Biosciences Corp) - Operating profit EBITDA|Operating profit EBITDA Ascentage Pharma Group International
